Summary Global Generics industry profile provides top-line qualitative and quantitative Summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Global generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information. - For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the generic-eligible market, are not included. - The global generics market is expected to generate total revenues of $271.2bn in 2015, representing a compound annual growth rate (CAGR) of 9% between 2011 and 2015. - Market consumption volume is forecast to reach a total... Research Beam Model: Research Beam Product ID: 533677 350 USD New
Global Generics
 
 

Global Generics

  • Category : Pharmaceuticals
  • Published On : January   2016
  • Pages : 33
  • Publisher : MarketLine
 
 
 
Summary
Global Generics industry profile provides top-line qualitative and quantitative Summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Global generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
- For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the generic-eligible market, are not included.
- The global generics market is expected to generate total revenues of $271.2bn in 2015, representing a compound annual growth rate (CAGR) of 9% between 2011 and 2015.
- Market consumption volume is forecast to reach a total of 82.2% of total pharma volume in 2015.
- The onset of the global economic crisis has led to several countries strengthening their generic policies. These policies have contributed to the strong growth experienced in this market in recent years.

Key Findings
Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the global
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the globalgenerics market
Leading company profiles reveal details of key generics market players global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Global generics market with five year forecasts by both value and volume

Reasons To Buy
What was the size of the Global generics market by value in 2015?
What will be the size of the Global generics market in 2020?
What factors are affecting the strength of competition in the Global generics market?
How has the market performed over the last five years?
How large is the globals generics market in relation to its regional counterparts?
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 9
Market value 9
Market volume 10
Market Segmentation 11
Geography segmentation 11
Market Outlook 12
Market value forecast 12
Market volume forecast 13
Five Forces Analysis 14
Summary 14
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Allergan plc 20
Mylan Inc. 23
Sandoz International GmbH 26
Teva Pharmaceutical Industries Limited 27
Methodology 30
Industry associations 31
Related MarketLine research 31
Appendix 32
About MarketLine 32

List of Tables
Table 1: Global generics market value: $ billion, 2011-15(e)
Table 2: Global generics market volume: % of total pharma volume, 2011-15(e)
Table 3: Global generics market geography segmentation: $ billion, 2015(e)
Table 4: Global generics market value forecast: $ billion, 2015-20
Table 5: Global generics market volume forecast: % of total pharma volume, 2015-20
Table 6: Allergan plc: key facts
Table 7: Allergan plc: key financials ($)
Table 8: Allergan plc: key financial ratios
Table 9: Mylan Inc.: key facts
Table 10: Mylan Inc.: key financials ($)
Table 11: Mylan Inc.: key financial ratios
Table 12: Sandoz International GmbH: key facts
Table 13: Teva Pharmaceutical Industries Limited: key facts
Table 14: Teva Pharmaceutical Industries Limited: key financials ($)
Table 15: Teva Pharmaceutical Industries Limited: key financial ratios

List of Figures
Figure 1: Global generics market value: $ billion, 2011-15(e)
Figure 2: Global generics market volume: % of total pharma volume, 2011-15(e)
Figure 3: Global generics market geography segmentation: % share, by value, 2015(e)
Figure 4: Global generics market value forecast: $ billion, 2015-20
Figure 5: Global generics market volume forecast: % of total pharma volume, 2015-20
Figure 6: Forces driving competition in the global generics market, 2015
Figure 7: Drivers of buyer power in the global generics market, 2015
Figure 8: Drivers of supplier power in the global generics market, 2015
Figure 9: Factors influencing the likelihood of new entrants in the global generics market, 2015
Figure 10: Factors influencing the threat of substitutes in the global generics market, 2015
Figure 11: Drivers of degree of rivalry in the global generics market, 2015
Figure 12: Allergan plc: revenues and profitability
Figure 13: Allergan plc: assets and liabilities
Figure 14: Mylan Inc.: revenues and profitability
Figure 15: Mylan Inc.: assets and liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues and profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets and liabilities

List Of Tables
N/A

List Of Figures
N/A
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT